NL-OMON24998
Recruiting
Not Applicable
Randomized, double-blind, placebo-controlled study to characterize the immune response after repeated KLH immunizations in healthy volunteers
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- CHDR
- Enrollment
- 12
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
.A.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Signed informed consent prior to any study\-mandated procedure;
- •2\. Healthy male subjects, 18 to 45 years of age (inclusive). Health status is defined by absence or evidence of any
- •active or chronic disease following a detailed medical and surgical history, a complete physical examination
- •including vital signs, 12\-lead ECG, haematology, blood chemistry, blood serology and urinalysis. In the case of
- •uncertain or questionable results, tests performed during screening may be repeated before randomization to
- •confirm eligibility or judged to be clinically irrelevant for healthy subjects;
- •3\. Body mass index (BMI) between 18 and 30 kg/m2, inclusive, and with a minimum bodyweight of 50 kg;’
- •4\. Fitzpatrick skin type I\-III.
- •5\. Has the ability to communicate well with the Investigator in the Dutch language and willing and able to comply
- •with the study restrictions.
Exclusion Criteria
- •1\. Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator (following a detailed medical history, physical examination, vital signs (systolic and diastolic blood pressure, pulse rate, body temperature) and 12\-lead electrocardiogram (ECG)). Minor deviations from the normal range may be accepted, if judged by the Investigator to have no clinical relevance;
- •2\. Clinically significant abnormalities, as judged by the Investigator, in laboratory test results (including haematology panel, chemistry panel and urinalysis). In the case of uncertain or questionable results, tests
- •performed during screening may be repeated before randomization to confirm eligibility or judged to be clinically irrelevant for healthy subjects;
- •3\. Positive Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening;
- •4\. Any disease associated with immune system impairment, including immune mediated diseases, transplantation patients and any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug or multiple drug allergies (non\-active hay fever is acceptable);
- •5\. Use of any medications (prescription or over\-the\-counter \[OTC]), within 21 days prior to initial KLH immunization, or less than 5 half\-lives (whichever is longer). An exception is made for paracetamol (up to 4 g/day). Other exceptions will only be made if the rationale is clearly documented by the Investigator;
- •6\. Use of immunosuppressive or immunomodulatory medication within 30 days prior to initial KLH immunization or planned to use during the course of the study;
- •7\. Any vaccination within 30 days prior to initial KLH immunization or planned during the course of the study with exception of vaccination for SARS\-CoV\-2;
- •8\. Vaccination for SARS\-CoV\-2 within 14 days prior to initial KLH immunization, or planned during the course of the study;
- •9\. Use of antibiotic therapy within 90 days prior to initial KLH immunization or planned to use during the course of the study;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Magnesium oxide to reduce prostate motion.1. Prostate cancer<br />2. radiotherapy.<br />(NLD: prostaatkanker, bestraling).NL-OMON24191niversity Medical Center Utrecht, The Netherlands184
Completed
Not Applicable
Randomized, double blind, placebo controlled trial of intramyocardial injection of autologous bone marrow cells in no-option patients with refractory angina pectoris and documented ischemia.Refractory angina pectoris and documented myocardial ischemia.NL-OMON29227Departmartement of Cardiology,Leiden University Medical Center ,Leiden, the Netherlands50
Completed
Not Applicable
Alfentanil in CT-colonography.PainCt-colonographyColorectal cancerPolypsNL-OMON25320Academic Medical Center90
Completed
Not Applicable
Efficacy and safety of ezetimibe in young children with familial hypercholesterolemia.Familial hypercholesterolemiaNL-OMON25426Academic Medical Centre (AMC), Department of Vascular Medicine70
Recruiting
Not Applicable
Het effect van fenretinide op insulinegevoeligheid.ObesityMetabolic syndrome XInsulin resistanceFatty liverNL-OMON25232Academic Medical Center (AMC)20